Bellicum presents new translational data for bpx-601 at asco gi cancers symposium

Houston, jan. 24, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new phase 1 translational results for bpx-601 at the american society of clinical oncology gastrointestinal cancers symposium (asco gi) in san francisco. the poster titled “ tumor infiltration and cytokine biomarkers of prostate stem cell antigen (psca)-directed gocar-t cells in patients with advanced pancreatic tumors ” presented new data from a cohort treated with bpx-601 and a single dose of rimiducid that showed immunomodulation in both the periphery and tumor microenvironment and provided additional insights into surrogate biomarkers of imc-mediated gocar-t® activity.
BLCM Ratings Summary
BLCM Quant Ranking